Pegylated darbepoetin alfa biosimilar (Merck & Co.)

聚乙二醇化达比泊汀α生物类似药 (Merck & Co.)

Report date: 2022/07/04 19:38:02

Base Information

Drug NamePegylated darbepoetin alfa biosimilar (Merck & Co.)
Drug Alias NameErythropoietin biosimilar - Merck聚乙二醇化达比泊汀α生物仿制药 (Merck & Co.)Recombinant PEG-erythropoietin biosimilar - MerckMK-2578
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionErythropoietin receptor agonists
TargetsErythropoietin receptor
Therapy Area/IndicationsAnemiaRenal Insufficiency, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck Sharp & Dohme LLC
Active IndicationsN/A
Inactive IndicationsAnemiaRenal Insufficiency, Chronic

Other Information

ATC CodeN/A
Related LinksN/A